CPT 82627: Dehydroepiandrosterone–Sulfate (DHEA‑S) Measurement
Commercial payers pay $66 on average nationally for this procedure.
CPT code 82627 reports laboratory measurement of dehydroepiandrosterone–sulfate (DHEA‑S), a steroid precursor used to evaluate adrenal hormone function; the service is a clinical chemistry endocrine assay (laboratory analysis) typically performed in an outpatient laboratory or hospital clinical laboratory setting to assist in assessing conditions such as adrenal hyperplasia, adrenal neoplasm, ovarian disorders, Cushing’s disease, or disorders related to delayed puberty and hirsutism.
For related coverage guidance, see recent payer policy updates: Salivary Hormone Testing, Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing, Bone Turnover Markers Testing.
Customize your policy alerts
Sign up for cpt 82627 policy alerts
Get alerted when payer policies referencing 82627 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial rates for CPT 82627 cluster around BUCA’s average commercial benchmark of $66.10, with notable variation across national payers. Blue Cross Blue Shield shows the highest central tendency (median $91.60) and a wide upper tail (max $313.40), while Aetna and Cigna sit closer to BUCA’s midpoint with medians of $18.30 and $19.90 respectively. UnitedHealth Group’s median of $13.30 is lower than BUCA, and BUCA’s published mean of $66.10 represents the broader commercial market center used here.
Dispersion measured by the interquartile range (P75–P25) is narrowest for Aetna at $9.10 (P75 $25.70 minus P25 $16.00) and widest for Blue Cross Blue Shield at $39.60 (P75 $117.80 minus P25 $82.59). UnitedHealth Group and Cigna have intermediate dispersion of $12.20 and $19.40 respectively, indicating more variability with Blue Cross Blue Shield driving the largest spread in commercial pricing for this code.